This is a single-centre, open label study, aiming to evaluate the efficacy of beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg nebulized), on airway resistance and reactances (measured with Rint and FOT techniques) in children with recurrent wheezing, aged 2-5 years. In addition, clinic score as frequency of symptoms and exacerbations, will be assessed.

Inclusion Criteria:

• Informed and subscribed consent before any procedure
• Age range : 2 - ≤5 years
• Male and female patients
• Recurrent wheezing affected ( ≥ 4 episodes in the last 12 months)
• PAI positive (at least one primary and two secondary ):

Primary:

1. one parent with asthma
2. Atopic Dermatitis
3. sensibilisation to air allergen

Secondary:

1. Food sensibilization
2. wheezing also not during the infective episodes
3. eosinophilia (>4%)

Exclusion Criteria:

• story of severe wheeze requiring hospitalization
• treatment with inhaled glucocorticoids during the previous 4 weeks or with oral glucocorticoids in the previous 8 weeks
• structural abnormalities of the lungs (tracheobronchial bronchomalacia, external compressions, etc)
• Persistent infections
• aspiration lung disease (gastroesophageal reflux disease, etc.)
• Cystic fibrosis
• prematurity or bronchopulmonary dysplasia
• Tuberculosis
• primary ciliary dyskinesia
• congenital heart disease
• pulmonary foreign body
• bronchiectasis
• Immunodeficit